The Potential Role of Phytonutrients Flavonoids Influencing Gut Microbiota in the Prophylaxis and Treatment of Inflammatory Bowel Disease

Abstract

Inflammatory bowel disease (IBD), characterized by the chronic inflammation of the gastrointestinal tract, is comprised of two idiopathic chronic intestinal inflammatory diseases. As the incidence of IBD increases, so does the need for safe and effective treatments. Trillions of microorganisms are colonized in the mammalian intestine, coevolve with the host in a symbiotic relationship. Gut microbiota has been reported to be involved in the pathophysiology of IBD. In this regard, phytonutrients flavonoids have received increasing attention for their anti-oxidant and anti-inflammatory activities. In this review, we address recent advances in the interactions among flavonoids, gut microbiota, and IBD. Moreover, their possible potential mechanisms of action in IBD have been discussed. We conclude that there is a complex interaction between flavonoids and gut microbiota. It is expected that flavonoids can change or reshape the gut microbiota to provide important considerations for developing treatments for IBD.

Probiotics (Lactiplantibacillus plantarum HNU082) supplementation relieves ulcerative colitis by affecting intestinal barrier functions, immunity-related genes expression, gut microbiota, and metabolic pathways in mice

“…Numerous studies have shown that probiotics improve the clinical outcome of IBD patients by in uencing host gut microbiota [32]. Herein, we performed a shotgun metagenomic analysis to investigate whether Lp082 can improve gut dysbiosis in the UC mice model.…”

Enhancing the Cognitive Effects of Flavonoids With Physical Activity: Is There a Case for the Gut Microbiome?

“…without inhibition of commensal bacteria (clostridia and lactobacilli) has been linked to prebiotic polyphenol intake ( Lee et al, 2006 ; Tuohy et al, 2012 ; Duda-Chodak et al, 2015 ). Separate in vivo feeding trials with berry species (cranberry and grape) led to consistent decrease in proportion of Firmicutes to Bacteroidetes, and remarkable increase in growth of Akkermansia muciniphila in the microbial community ( Anhe et al, 2014 ; Roopchand et al, 2015 ; Wang et al, 2021 ).…”

“…and Bifidobacteria spp. and inhibiting gut pathogens ( Wang et al, 2021 ). Reduced abundance of pathogenic bacteria in the gut ( Clostridium perfringens , C. difficile , and gram-negative Bacteroides spp.)…”

The semi-synthetic flavonoid 2′,3′,4′-trihydroxyflavone (2-D08) inhibits both SN-38- and cytokine-evoked increases in epithelial barrier permeability in anin vitrointestinal mucositis model

“…[77][78][79][80][81] Dietary polyphenols such as flavonoids play an important role in maintaining intestinal homeostasis and possess the ability to modulate the gut microbiome in a variety of ways, such as influencing the abundance of various pathogenic bacteria, and may play a role in the amelioration of IBD-associated dysbiosis. 82,83 In this light, future studies focusing on novel flavonoids such as 2-D08, transilitin and myricetin and their effects on intestinal pathologies linked to dysbiosis are warranted. Interestingly, topoisomerase 1, the primary target of irinotecan, has been identified as a substrate for SUMOylation, with SUMOylation playing an important role in the nucleolar delocalisation of this protein.…”